Adam S. Kibel, MD

Adam S. Kibel, MD

Surgical Oncology

Contact Information

Office Phone Number

617-525-7697

Fax

617-566-3475

Appointments

877-332-4294 (new)

Researcher

Physician

Disease Center Leader, Urology
Chief, Urologic Surgery, Brigham and Women's Hospital
Professor of Surgery, Harvard Medical School

Centers/Programs

Bladder Cancer

Clinical Interests

Bladder cancer, Kidney cancer, Minimally-invasive surgical treatments for urologic cancers, Prostate cancer, Robotic surgery for urologic cancers, Testicular cancer

Board Certification

  • Urology, 2001

Fellowship

  • Johns Hopkins Hospital, Urologic Oncology

Residency

  • Brigham and Women's Hospital, General Surgery
  • Harvard Program in Urology

Medical School

  • Cornell University Medical School

Publications

    • The effect of limited english proficiency on prostate-specific antigen screening in American men. World J Urol. 2024 Jan 20; 42(1):54. View in: Pubmed

    • A Phase II Prospective Blinded Trial of Magnetic Resonance Imaging and In-Bore Biopsy in Active Surveillance for Prostate Cancer. Urology. 2024 Jan 11. View in: Pubmed

    • Prostate cancer screening in African American men: a review of the evidence. J Natl Cancer Inst. 2024 Jan 10; 116(1):34-52. View in: Pubmed

    • Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18 months of perioperative androgen-deprivation therapy in men with localized, unfavorable intermediate-risk or high-risk prostate cancer: Results of part 2 of a randomized phase 2 trial. Cancer. 2024 Jan 01. View in: Pubmed

    • The Association of County-level Prostate-specific Antigen Screening with Metastatic Prostate Cancer and Prostate Cancer Mortality. Eur Urol Oncol. 2023 Dec 27. View in: Pubmed

    • Climate change perception and its association with cancer screening intent. J Natl Cancer Inst. 2023 Dec 13. View in: Pubmed

    • Impact of COVID-19 pandemic on ambulatory urologic oncology surgeries. Can J Urol. 2023 Dec; 30(6):11714-11723. View in: Pubmed

    • Adjuvant and salvage radiotherapy after neoadjuvant therapy and radical prostatectomy for high-risk localized prostate cancer. Prostate. 2024 Mar; 84(4):342-348. View in: Pubmed

    • Reply by Authors. Urol Pract. 2024 Jan; 11(1):85. View in: Pubmed

    • Long-Term Impact of Medicaid Expansion on Prostate Cancer Screening. Urol Pract. 2024 Jan; 11(1):78-84. View in: Pubmed

    • Racial differences in knowledge, attitudes, and sources of information about germline cancer genetic testing in the U.S.A.: An analysis of the health information National Trends Survey System. Prev Med. 2024 Jan; 178:107779. View in: Pubmed

    • Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants. Nat Genet. 2023 Dec; 55(12):2065-2074. View in: Pubmed

    • Evidence-Based Analysis of the Critical Steps of Radical Cystectomy for Bladder Cancer. J Clin Med. 2023 Oct 30; 12(21). View in: Pubmed

    • Bladder cancer patient and provider perspectives on smoking cessation. Urol Oncol. 2023 Nov; 41(11):457.e9-457.e16. View in: Pubmed

    • Uncovering the Changing Treatment Landscape for Low-risk Prostate Cancer in the USA from 2010 to 2020: Insights from the National Cancer Data Base. Eur Urol. 2023 Dec; 84(6):527-530. View in: Pubmed

    • Racial differences in patient-reported outcomes among men treated with radical prostatectomy for prostate cancer. Prostate. 2024 Jan; 84(1):47-55. View in: Pubmed

    • Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy. Urol Oncol. 2023 Nov; 41(11):458.e1-458.e7. View in: Pubmed

    • Racial Disparities in Prostate Cancer Screening: The Role of Shared Decision Making. Am J Prev Med. 2024 Jan; 66(1):27-36. View in: Pubmed

    • Stereotactic Magnetic Resonance-guided Adaptive Radiation Therapy for Localized Kidney Cancer: Early Outcomes from a Prospective Phase 1 Trial and Supplemental Cohort. Eur Urol Oncol. 2024 Feb; 7(1):147-150. View in: Pubmed

    • Changes in Prostate-specific Antigen Screening after the 2018 United States Preventive Services Task Force Recommendations and Through the COVID-19 Pandemic. Eur Urol Oncol. 2024 Feb; 7(1):151-154. View in: Pubmed

    • Predictors of Financial Toxicity Among United States Prostate Cancer Survivors: Results From a National Survey. Urol Pract. 2023 09; 10(5):459-466. View in: Pubmed

    • Disparities in Travel-Related Barriers to Accessing Health Care From the 2017 National Household Travel Survey. JAMA Netw Open. 2023 07 03; 6(7):e2325291. View in: Pubmed

    • Free PSA and Clinically Significant and Fatal Prostate Cancer in the PLCO Screening Trial. J Urol. 2023 10; 210(4):630-638. View in: Pubmed

    • Agent Orange exposure and prostate cancer risk in the Million Veteran Program. medRxiv. 2023 Jun 16. View in: Pubmed

    • MRI-Targeted, Systematic, or Combined Biopsy for Detecting Clinically Significant Prostate Cancer. J Am Coll Radiol. 2023 07; 20(7):687-695. View in: Pubmed

    • Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry. Am J Hum Genet. 2023 07 06; 110(7):1200-1206. View in: Pubmed

    • Institutional trends and safety profile of same-day discharge for robot-assisted laparoscopic radical prostatectomy: A retrospective analysis. Urol Oncol. 2023 08; 41(8):354.e19-354.e26. View in: Pubmed

    • The Risk of Catastrophic Healthcare Expenditures Among Prostate and Bladder Cancer Survivors in the United States. Clin Genitourin Cancer. 2023 Dec; 21(6):617-625. View in: Pubmed

    • Evaluating Approaches for Constructing Polygenic Risk Scores for Prostate Cancer in Men of African and European Ancestry. medRxiv. 2023 May 15. View in: Pubmed

    • Effect of type of definitive treatment on race-based differences in prostate cancer-specific survival. Prostate. 2023 Aug; 83(11):1099-1111. View in: Pubmed

    • PI-RADS 3 score: A retrospective experience of clinically significant prostate cancer detection. BJUI Compass. 2023 Jul; 4(4):473-481. View in: Pubmed

    • Contemporary patterns of local ablative therapies for prostate cancer at United States cancer centers: results from a national registry. World J Urol. 2023 May; 41(5):1309-1315. View in: Pubmed

    • Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry. Eur Urol. 2023 07; 84(1):13-21. View in: Pubmed

    • NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023. J Natl Compr Canc Netw. 2023 03; 21(3):236-246. View in: Pubmed

    • Association between Presurgical Weight Status and Urinary and Sexual Function in Prostate Cancer Patients Treated by Radical Prostatectomy: A Prospective Cohort Study. Urology. 2023 05; 175:137-143. View in: Pubmed

    • Is Segmental Ureterectomy Associated with Inferior Survival for Localized Upper-Tract Urothelial Carcinoma of the Ureter Compared to Radical Nephroureterectomy? Cancers (Basel). 2023 Feb 21; 15(5). View in: Pubmed

    • Addition of a Genetic Risk Score for Identification of Men with a Low Prostate-specific Antigen Level in Midlife at Risk of Developing Lethal Prostate Cancer. Eur Urol Open Sci. 2023 Apr; 50:27-30. View in: Pubmed

    • Gaining metabolic insight in older men undergoing androgen deprivation therapy for prostate cancer (the ADT & Metabolism Study): Protocol of a longitudinal, observational, cohort study. PLoS One. 2023; 18(2):e0281508. View in: Pubmed

    • Assessment of the Ecological Association between Tobacco Smoking Exposure and Bladder Cancer Incidence over the Past Half-Century in the United States. Curr Oncol. 2023 02 06; 30(2):1986-1998. View in: Pubmed

    • Feasibility of multi-section continuum robotic ureteroscope in the kidney. J Robot Surg. 2023 Aug; 17(4):1411-1420. View in: Pubmed

    • CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer. Nat Commun. 2023 01 17; 14(1):252. View in: Pubmed

    • Racial Differences in Germline Genetic Testing for Prostate Cancer: A Systematic Review. JCO Oncol Pract. 2023 05; 19(5):e784-e793. View in: Pubmed

    • Family History of Prostate and Breast Cancer Integrated with a Polygenic Risk Score Identifies Men at Highest Risk of Dying from Prostate Cancer before Age 75 Years. Clin Cancer Res. 2022 Nov 14; 28(22):4926-4933. View in: Pubmed

    • Understanding Hospital-Level Patterns of Nonoperative Management for Low-risk Thyroid and Kidney Cancer. JAMA Netw Open. 2022 11 01; 5(11):e2242210. View in: Pubmed

    • Radiologists' Contribution to Variation in Detecting Clinically Significant Prostate Cancer in Men With Prostate MRI. J Am Coll Radiol. 2022 12; 19(12):1312-1321. View in: Pubmed

    • Testosterone replacement in prostate cancer survivors with testosterone deficiency: Study protocol of a randomized controlled trial. Andrology. 2023 01; 11(1):93-102. View in: Pubmed

    • Comparison of Long-term Outcomes for Young and Healthy Patients with cT1a and cT3a Renal Cell Carcinoma Treated with Partial Nephrectomy. Eur Urol Focus. 2023 03; 9(2):333-335. View in: Pubmed

    • Neoadjuvant Novel Hormonal Therapy Followed by Prostatectomy versus Up-Front Prostatectomy for High-Risk Prostate Cancer: A Comparative Analysis. J Urol. 2022 10; 208(4):838-845. View in: Pubmed

    • Impact of exercise on physical health status in bladder cancer patients. Can Urol Assoc J. 2022 Aug 30. View in: Pubmed

    • Incidence of Germline Variants in Familial Bladder Cancer and Among Patients With Cancer Predisposition Syndromes. Clin Genitourin Cancer. 2022 Dec; 20(6):568-574. View in: Pubmed

    • Validation of a multi-ancestry polygenic risk score and age-specific risks of prostate cancer: A meta-analysis within diverse populations. Elife. 2022 07 08; 11. View in: Pubmed

    • 5-Alpha Reductase Inhibitors and Prostate Cancer Mortality among Men with Regular Access to Screening and Health Care. Cancer Epidemiol Biomarkers Prev. 2022 07 01; 31(7):1460-1465. View in: Pubmed

    • Renaming Gleason Score 6 Prostate to Noncancer: A Flawed Idea Scientifically and for Patient Care. J Clin Oncol. 2022 09 20; 40(27):3106-3109. View in: Pubmed

    • MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study. Lancet Oncol. 2022 07; 23(7):910-918. View in: Pubmed

    • Preoperative anemia is associated with increased radical cystectomy complications. Urol Oncol. 2022 08; 40(8):382.e7-382.e13. View in: Pubmed

    • A Healthy Lifestyle in Men at Increased Genetic Risk for Prostate Cancer. Eur Urol. 2023 04; 83(4):343-351. View in: Pubmed

    • Evaluation of a Multiethnic Polygenic Risk Score Model for Prostate Cancer. J Natl Cancer Inst. 2022 05 09; 114(5):771-774. View in: Pubmed

    • Hormone Treatment of Prostate Cancer:: Evidence for Usage and Safety. Urol Clin North Am. 2022 May; 49(2):309-321. View in: Pubmed

    • Association between Operative Time and Short-Term Radical Cystectomy Complications. Urol Int. 2023; 107(3):273-279. View in: Pubmed

    • RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer. Sci Adv. 2022 02 18; 8(7):eabl9794. View in: Pubmed

    • Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score. Prostate Cancer Prostatic Dis. 2022 04; 25(4):755-761. View in: Pubmed

    • Videos of Sipuleucel-T Programmed T Cells Lysing Cells That Express Prostate Cancer Target Antigens. J Natl Cancer Inst. 2022 02 07; 114(2):310-313. View in: Pubmed

    • Metabolic syndrome and its pharmacologic treatment are associated with the time to castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2022 02; 25(2):320-326. View in: Pubmed

    • A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry. Eur Urol. 2022 05; 81(5):458-462. View in: Pubmed

    • DNA Repair Pathways and Their Association With Lethal Prostate Cancer in African American and European American Men. JNCI Cancer Spectr. 2022 02; 6(1). View in: Pubmed

    • Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy. Eur Urol. 2022 05; 81(5):466-473. View in: Pubmed

    • The Translational and Regulatory Development of an Implantable Microdevice for Multiple Drug Sensitivity Measurements in Cancer Patients. IEEE Trans Biomed Eng. 2022 01; 69(1):412-421. View in: Pubmed

    • A Pilot Study of Multidimensional Diffusion MRI for Assessment of Tissue Heterogeneity in Prostate Cancer. Invest Radiol. 2021 12 01; 56(12):845-853. View in: Pubmed

    • Epidemiology and Prevention of Prostate Cancer. Eur Urol Oncol. 2021 12; 4(6):877-892. View in: Pubmed

    • Adverse Histopathologic Characteristics in Small Papillary Renal Cell Carcinomas Have Minimal Impact on Prognosis. Am J Clin Pathol. 2021 Sep 08; 156(4):550-558. View in: Pubmed

    • Prospective Multicenter Comparison of Open and Robotic Radical Prostatectomy: The PROST-QA/RP2 Consortium. J Urol. 2022 01; 207(1):127-136. View in: Pubmed

    • A Selective Androgen Receptor Modulator (OPK-88004) in Prostate Cancer Survivors: A Randomized Trial. J Clin Endocrinol Metab. 2021 07 13; 106(8):2171-2186. View in: Pubmed

    • Performance of African-ancestry-specific polygenic hazard score varies according to local ancestry in 8q24. Prostate Cancer Prostatic Dis. 2022 02; 25(2):229-237. View in: Pubmed

    • Cyclophosphamide-associated bladder cancers and considerations for survivorship care: A systematic review. Urol Oncol. 2021 10; 39(10):678-685. View in: Pubmed

    • Domain adaptation for segmentation of critical structures for prostate cancer therapy. Sci Rep. 2021 06 01; 11(1):11480. View in: Pubmed

    • Racial and Ethnic Variation in PSA Testing and Prostate Cancer Incidence Following the 2012 USPSTF Recommendation. J Natl Cancer Inst. 2021 06 01; 113(6):719-726. View in: Pubmed

    • One-year urinary and sexual outcome trajectories among prostate cancer patients treated by radical prostatectomy: a prospective study. BMC Urol. 2021 May 17; 21(1):81. View in: Pubmed

    • Effect of Medicaid Expansion on Receipt of Definitive Treatment and Time to Treatment Initiation by Racial and Ethnic Minorities and at Minority-Serving Hospitals: A Patient-Level and Facility-Level Analysis of Breast, Colon, Lung, and Prostate Cancer. JCO Oncol Pract. 2021 05; 17(5):e654-e665. View in: Pubmed

    • KLK3 SNP-SNP interactions for prediction of prostate cancer aggressiveness. Sci Rep. 2021 04 29; 11(1):9264. View in: Pubmed

    • Is Medicaid expansion associated with increases in palliative treatments for metastatic cancer? J Comp Eff Res. 2021 06; 10(9):733-741. View in: Pubmed

    • Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer. Eur Urol. 2021 09; 80(3):295-303. View in: Pubmed

    • Delay in surgery for cT1b-2 kidney cancer beyond 90 days is associated with poorer survival: implications for prioritization during the COVID-19 pandemic. Minerva Urol Nephrol. 2021 06; 73(3):404-406. View in: Pubmed

    • EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nat Cancer. 2021 04; 2(4):444-456. View in: Pubmed

    • Impact of high-intensity local treatment on overall survival in stage IV upper tract urothelial carcinoma. Urol Oncol. 2021 07; 39(7):436.e1-436.e10. View in: Pubmed

    • Reply by Authors. J Urol. 2021 05; 205(5):1274. View in: Pubmed

    • Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer. J Urol. 2021 07; 206(1):80-87. View in: Pubmed

    • Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat Genet. 2021 Mar; 53(3):413. View in: Pubmed

    • Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. Nat Commun. 2021 02 23; 12(1):1236. View in: Pubmed

    • Outcomes of Post-Neoadjuvant Intense Hormone Therapy and Surgery for High Risk Localized Prostate Cancer: Results of a Pooled Analysis of Contemporary Clinical Trials. J Urol. 2021 06; 205(6):1689-1697. View in: Pubmed

    • Systematic Review of Time to Definitive Treatment for Intermediate Risk and High Risk Prostate Cancer: Are Delays Associated with Worse Outcomes? J Urol. 2021 May; 205(5):1263-1274. View in: Pubmed

    • Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. Prostate Cancer Prostatic Dis. 2021 06; 24(2):532-541. View in: Pubmed

    • Insulinemic and Inflammatory Dietary Patterns and Risk of Prostate Cancer. Eur Urol. 2021 03; 79(3):405-412. View in: Pubmed

    • Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat Genet. 2021 01; 53(1):65-75. View in: Pubmed

    • The impact of smoking on radical cystectomy complications increases in elderly patients. Cancer. 2021 05 01; 127(9):1387-1394. View in: Pubmed

    • Health care spending in prostate cancer: An assessment of characteristics and health care utilization of high resource-patients. Urol Oncol. 2021 02; 39(2):130.e17-130.e24. View in: Pubmed

    • Assessment of Time-to-Treatment Initiation and Survival in a Cohort of Patients With Common Cancers. JAMA Netw Open. 2020 12 01; 3(12):e2030072. View in: Pubmed

    • Recovery from minimally invasive vs. open surgery in kidney cancer patients: Opioid use and workplace absenteeism. Investig Clin Urol. 2021 01; 62(1):56-64. View in: Pubmed

    • Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum. Mol Cancer Res. 2021 03; 19(3):475-484. View in: Pubmed

    • The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor. Cancers (Basel). 2020 Nov 04; 12(11). View in: Pubmed

    • Mobile Health App for Prostate Cancer Patients on Androgen Deprivation Therapy: Qualitative Usability Study. JMIR Mhealth Uhealth. 2020 11 03; 8(11):e20224. View in: Pubmed

    • Access denied: The relationship between patient insurance status and access to high-volume hospitals. Cancer. 2021 02 15; 127(4):577-585. View in: Pubmed

    • Association of surgical approach and prolonged opioid prescriptions in patients undergoing major pelvic cancer procedures. BMC Surg. 2020 Oct 14; 20(1):235. View in: Pubmed

    • 'Case of the Month' from Brigham and Women's Hospital, Boston, MA, USA: a 70-year-old man with lung cysts and bilateral renal masses. BJU Int. 2020 10; 126(4):428-432. View in: Pubmed

    • African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer. Int J Cancer. 2021 01 01; 148(1):99-105. View in: Pubmed

    • Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I. J Urol. 2021 Jan; 205(1):14-21. View in: Pubmed

    • Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II. J Urol. 2021 Jan; 205(1):22-29. View in: Pubmed

    • A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data. Cancer Epidemiol Biomarkers Prev. 2020 09; 29(9):1731-1738. View in: Pubmed

    • Delayed blood transfusion is associated with mortality following radical cystectomy. Scand J Urol. 2020 Aug; 54(4):290-296. View in: Pubmed

    • The effect of sample size on polygenic hazard models for prostate cancer. Eur J Hum Genet. 2020 10; 28(10):1467-1475. View in: Pubmed

    • AUTHOR REPLY. Urology. 2020 06; 140:121. View in: Pubmed

    • A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry. Eur Urol. 2020 09; 78(3):316-320. View in: Pubmed

    • EDITORIAL COMMENT. Urology. 2020 05; 139:42-43. View in: Pubmed

    • Workplace absenteeism amongst patients undergoing open vs. robotic radical prostatectomy, hysterectomy, and partial colectomy. Surg Endosc. 2021 04; 35(4):1644-1650. View in: Pubmed

    • Alvimopan Is Associated With a Reduction in Length of Stay and Hospital Costs for Patients Undergoing Radical Cystectomy. Urology. 2020 06; 140:115-121. View in: Pubmed

    • Quantifying the Overall Survival Benefit With Early Radical Cystectomy for Patients With Histologically Confirmed T1 Non-muscle-invasive Bladder Cancer. Clin Genitourin Cancer. 2020 12; 18(6):e651-e659. View in: Pubmed

    • Geographic Distribution of Racial Differences in Prostate Cancer Mortality. JAMA Netw Open. 2020 03 02; 3(3):e201839. View in: Pubmed

    • miR-218 Expressed in Endothelial Progenitor Cells Contributes to the Development and Repair of the Kidney Microvasculature. Am J Pathol. 2020 03; 190(3):642-659. View in: Pubmed

    • Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer: The MEAL Randomized Clinical Trial. JAMA. 2020 01 14; 323(2):140-148. View in: Pubmed

    • Minimally invasive cancer surgery is associated with a lower risk of venous thromboembolic events. J Surg Oncol. 2020 Mar; 121(3):578-583. View in: Pubmed

    • Assessment of Out-of-Pocket Costs for Robotic Cancer Surgery in US Adults. JAMA Netw Open. 2020 01 03; 3(1):e1919185. View in: Pubmed

    • Delayed nephrectomy has comparable long-term overall survival to immediate nephrectomy for cT1a renal cell carcinoma: A population-based analysis. Urol Oncol. 2020 03; 38(3):74.e13-74.e20. View in: Pubmed

    • Facility-Level Variation in Pelvic Lymphadenectomy During Radical Prostatectomy and Effect on Overall Survival in Men with High-Risk Prostate Cancer. Ann Surg Oncol. 2020 Jun; 27(6):1929-1936. View in: Pubmed

    • Risk of dementia following androgen deprivation therapy for treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2020 09; 23(3):410-418. View in: Pubmed

    • Risk factors and reasons for reoperation after radical cystectomy. Urol Oncol. 2020 04; 38(4):269-277. View in: Pubmed

    • Clinical Utility of a Genomic Classifier in Men Undergoing Radical Prostatectomy: The PRO-IMPACT Trial. Pract Radiat Oncol. 2020 Mar - Apr; 10(2):e82-e90. View in: Pubmed

    • Differences in survival and impact of adjuvant chemotherapy in patients with variant histology of tumors of the renal pelvis. World J Urol. 2020 Sep; 38(9):2227-2236. View in: Pubmed

    • Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma. J Immunother Cancer. 2019 11 07; 7(1):289. View in: Pubmed

    • The impact of underinsurance on bladder cancer diagnosis, survival, and care delivery for individuals under the age of 65 years. Cancer. 2020 02 01; 126(3):496-505. View in: Pubmed

    • Risk of Dementia and Depression in Young and Middle-aged Men Presenting with Nonmetastatic Prostate Cancer Treated with Androgen Deprivation Therapy. Eur Urol Oncol. 2021 02; 4(1):66-72. View in: Pubmed

    • Trends in Adherence to Thromboprophylaxis Guideline in Patients Undergoing Radical Cystectomy. Urology. 2020 Jan; 135:44-49. View in: Pubmed

    • Adverse Histopathologic Characteristics in Small Clear Cell Renal Cell Carcinomas Have Negative Impact on Prognosis: A Study of 631 Cases With Clinical Follow-up. Am J Surg Pathol. 2019 10; 43(10):1413-1420. View in: Pubmed

    • Predictors of Recurrence, and Progression-Free and Overall Survival following Open versus Robotic Radical Cystectomy: Analysis from the RAZOR Trial with a 3-Year Followup. J Urol. 2020 03; 203(3):522-529. View in: Pubmed

    • Publisher Correction: Shared heritability and functional enrichment across six solid cancers. Nat Commun. 2019 Sep 23; 10(1):4386. View in: Pubmed

    • Comparing the Association Between Insurance and Mortality in Ovarian, Pancreatic, Lung, Colorectal, Prostate, and Breast Cancers. J Natl Compr Canc Netw. 2019 09 01; 17(9):1049-1058. View in: Pubmed

    • Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function. Proc Natl Acad Sci U S A. 2019 07 16; 116(29):14573-14582. View in: Pubmed

    • Contemporary national trends in prostate cancer risk profile at diagnosis. Prostate Cancer Prostatic Dis. 2020 03; 23(1):81-87. View in: Pubmed

    • Variation in Positive Surgical Margin Status After Radical Prostatectomy for pT2 Prostate Cancer. Clin Genitourin Cancer. 2019 10; 17(5):e1060-e1068. View in: Pubmed

    • The association of marital status and mortality among men with early-stage prostate cancer treated with radical prostatectomy: insight into post-prostatectomy survival strategies. Cancer Causes Control. 2019 Aug; 30(8):871-876. View in: Pubmed

    • Sex-specific Differences in the Quality of Treatment of Muscle-invasive Bladder Cancer Do Not Explain the Overall Survival Discrepancy. Eur Urol Focus. 2021 01; 7(1):124-131. View in: Pubmed

    • Comparison of Hospital Readmission After Total Hip and Total Knee Arthroplasty vs Spinal Surgery After Implementation of the Hospital Readmissions Reduction Program. JAMA Netw Open. 2019 05 03; 2(5):e194634. View in: Pubmed

    • The current landscape of low-value care in men diagnosed with prostate cancer: what is the role of individual hospitals? Urol Oncol. 2019 09; 37(9):575.e9-575.e18. View in: Pubmed

    • The bladder cancer conundrum: how do we treat the right tumour with the right treatment, at the right time? BJU Int. 2019 05; 123(5):748-749. View in: Pubmed

    • Impact of Accountable Care Organizations on Prostate Cancer Screening and Biopsies in the United States. Urol Pract. 2019 May; 6(3):159-164. View in: Pubmed

    • Recommended Cancer Screening in Accountable Care Organizations: Trends in Colonoscopy and Mammography in the Medicare Shared Savings Program. J Oncol Pract. 2019 06; 15(6):e547-e559. View in: Pubmed

    • Examining the relationship between complications and perioperative mortality following radical cystectomy: a population-based analysis. BJU Int. 2019 07; 124(1):40-46. View in: Pubmed

    • Prostate cancer in the medicare shared savings program: are Accountable Care Organizations associated with reduced expenditures for men with prostate cancer? Prostate Cancer Prostatic Dis. 2019 12; 22(4):593-599. View in: Pubmed

    • Facility Level Variation in Rates of Definitive Therapy for Low Risk Prostate Cancer in Men with Limited Life Expectancy: An Opportunity for Value Based Care Redesign. J Urol. 2019 04; 201(4):728-734. View in: Pubmed

    • Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals. J Urol. 2019 04; 201(4):735-741. View in: Pubmed

    • Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone. J Clin Oncol. 2019 04 10; 37(11):923-931. View in: Pubmed

    • Comparing Long-Term Outcomes Following Radical and Partial Nephrectomy for cT1 Renal Cell Carcinoma in Young and Healthy Individuals. JNCI Cancer Spectr. 2019 Mar; 3(1):pkz003. View in: Pubmed

    • Association of Care at Minority-Serving vs Non-Minority-Serving Hospitals With Use of Palliative Care Among Racial/Ethnic Minorities With Metastatic Cancer in the United States. JAMA Netw Open. 2019 02 01; 2(2):e187633. View in: Pubmed

    • Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet. 2019 02; 51(2):363. View in: Pubmed

    • Contemporary Survival Rates for Muscle-Invasive Bladder Cancer Treated With Definitive or Non-Definitive Therapy. Clin Genitourin Cancer. 2019 06; 17(3):e488-e493. View in: Pubmed

    • Shared heritability and functional enrichment across six solid cancers. Nat Commun. 2019 01 25; 10(1):431. View in: Pubmed

    • Author Correction: Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Nat Commun. 2019 01 17; 10(1):382. View in: Pubmed

    • A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Intravenous Acetaminophen Versus Placebo in Patients Undergoing Robotic-Assisted Laparoscopic Prostatectomy. J Pain Palliat Care Pharmacother. 2018 Jun - Sep; 32(2-3):82-89. View in: Pubmed

    • Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival? Cancer. 2019 04 15; 125(8):1319-1329. View in: Pubmed

    • Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter? Cancer. 2019 05 01; 125(9):1449-1458. View in: Pubmed

    • Re: Association of Robotic-Assisted vs Laparoscopic Radical Nephrectomy with Perioperative Outcomes and Health Care Costs, 2003 to 2015. Eur Urol. 2019 04; 75(4):696-697. View in: Pubmed

    • AA9int: SNP interaction pattern search using non-hierarchical additive model set. Bioinformatics. 2018 12 15; 34(24):4141-4150. View in: Pubmed

    • Levels and patterns of self-reported and objectively-measured free-living physical activity among prostate cancer survivors: A prospective cohort study. Cancer. 2019 03 01; 125(5):798-806. View in: Pubmed

    • Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories. World J Urol. 2019 Oct; 37(10):2059-2065. View in: Pubmed

    • Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status. Ann Surg Oncol. 2019 Jan; 26(1):297-305. View in: Pubmed

    • Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. Eur Urol. 2019 04; 75(4):552-555. View in: Pubmed

    • Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Nat Commun. 2018 11 05; 9(1):4616. View in: Pubmed

    • Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study. Cancer Epidemiol Biomarkers Prev. 2019 01; 28(1):208-216. View in: Pubmed

    • Use of Preventive Health Services Among Cancer Survivors in the U.S. Am J Prev Med. 2018 12; 55(6):830-838. View in: Pubmed

    • Mechanisms responsible for reduced erythropoiesis during androgen deprivation therapy in men with prostate cancer. Am J Physiol Endocrinol Metab. 2018 12 01; 315(6):E1185-E1193. View in: Pubmed

    • Multilevel Analysis of Readmissions After Radical Cystectomy for Bladder Cancer in the USA: Does the Hospital Make a Difference? Eur Urol Oncol. 2019 07; 2(4):349-354. View in: Pubmed

    • The impact of age at the time of radiotherapy for localized prostate cancer on the development of second primary malignancies. Urol Oncol. 2018 11; 36(11):500.e11-500.e19. View in: Pubmed

    • Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men. Eur Urol. 2019 03; 75(3):399-407. View in: Pubmed

    • Targeting the MIF/CXCR7/AKT Signaling Pathway in Castration-Resistant Prostate Cancer. Mol Cancer Res. 2019 01; 17(1):263-276. View in: Pubmed

    • Implementation of a Perioperative Venous Thromboembolism Prophylaxis Program for Patients Undergoing Radical Cystectomy on an Enhanced Recovery After Surgery Protocol. Eur Urol Focus. 2020 01 15; 6(1):74-80. View in: Pubmed

    • Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer. Prostate Cancer Prostatic Dis. 2019 03; 22(1):125-136. View in: Pubmed

    • Contemporary perceptions of human papillomavirus and penile cancer: Perspectives from a national survey. Can Urol Assoc J. 2019 Feb; 13(2):32-37. View in: Pubmed

    • Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. Lancet. 2018 06 23; 391(10139):2525-2536. View in: Pubmed

    • Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era. World J Urol. 2018 Nov; 36(11):1767-1774. View in: Pubmed

    • Contemporary trends in the utilisation of radical prostatectomy. BJU Int. 2018 11; 122(5):726-728. View in: Pubmed

    • Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nat Commun. 2018 06 11; 9(1):2256. View in: Pubmed

    • Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet. 2018 07; 50(7):928-936. View in: Pubmed

    • Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival. Clin Cancer Res. 2018 10 01; 24(19):4662-4671. View in: Pubmed

    • Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy. Eur Urol Oncol. 2018 06; 1(2):143-148. View in: Pubmed

    • Functional roles and potential clinical application of miRNA-345-5p in prostate cancer. Prostate. 2018 09; 78(12):927-937. View in: Pubmed

    • Current Staging Strategies for Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Cell Carcinoma. Urol Clin North Am. 2018 May; 45(2):143-154. View in: Pubmed

    • Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With Prostate Cancer. J Endocr Soc. 2018 May 01; 2(5):485-496. View in: Pubmed

    • Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer. J Urol. 2018 09; 200(3):573-581. View in: Pubmed

    • The effect of treatment at minority-serving hospitals on outcomes for bladder cancer. Urol Oncol. 2018 05; 36(5):238.e7-238.e17. View in: Pubmed

    • Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array. Br J Cancer. 2018 03 20; 118(6):e9. View in: Pubmed

    • Reassessing the value of high-volume cancer care in the era of precision medicine. Cancer. 2018 04 01; 124(7):1319-1321. View in: Pubmed

    • Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. J Urol. 2018 06; 199(6):1417-1425. View in: Pubmed

    • Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy. JAMA Oncol. 2018 Feb 01; 4(2):225-229. View in: Pubmed

    • Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. BMJ. 2018 01 10; 360:j5757. View in: Pubmed

    • The association of weight change in young adulthood and smoking status with risk of prostate cancer recurrence. Int J Cancer. 2018 05 15; 142(10):2011-2018. View in: Pubmed

    • Comparative effectiveness of robot-assisted vs. open radical cystectomy. Urol Oncol. 2018 03; 36(3):88.e1-88.e9. View in: Pubmed

    • Outcomes of Intracorporeal Urinary Diversion after Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. J Urol. 2018 05; 199(5):1302-1311. View in: Pubmed

    • Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade. Prostate Cancer Prostatic Dis. 2018 09; 21(3):364-372. View in: Pubmed

    • Editorial Comment. J Urol. 2018 03; 199(3):712. View in: Pubmed

    • Factors Influencing Prostate Specific Antigen Testing in the United States. Urol Pract. 2018 Nov; 5(6):438-443. View in: Pubmed

    • Impact of adequate pelvic lymph node dissection on overall survival after radical cystectomy: A stratified analysis by clinical stage and receipt of neoadjuvant chemotherapy. Urol Oncol. 2018 02; 36(2):78.e13-78.e19. View in: Pubmed

    • Associations of specific postoperative complications with costs after radical cystectomy. BJU Int. 2018 03; 121(3):428-436. View in: Pubmed

    • Approach to the Patient with High-Risk Prostate Cancer. Urol Clin North Am. 2017 Nov; 44(4):635-645. View in: Pubmed

    • Effects of Androgen Deprivation Therapy on Pain Perception, Quality of Life, and Depression in Men With Prostate Cancer. J Pain Symptom Manage. 2018 02; 55(2):307-317.e1. View in: Pubmed

    • Variation in the use of active surveillance for low-risk prostate cancer. Cancer. 2018 Jan 01; 124(1):55-64. View in: Pubmed

    • Androgen receptor-mediated downregulation of microRNA-221 and -222 in castration-resistant prostate cancer. PLoS One. 2017; 12(9):e0184166. View in: Pubmed

    • Effect of Nonurothelial Histologic Variants on the Outcomes of Radical Cystectomy for Nonmetastatic Muscle-invasive Urinary Bladder Cancer. Clin Genitourin Cancer. 2017 Aug 24. View in: Pubmed

    • Exploring exposure to Agent Orange and increased mortality due to bladder cancer. Urol Oncol. 2017 11; 35(11):627-632. View in: Pubmed

    • Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA. Eur Urol. 2018 Mar; 73(3):374-382. View in: Pubmed

    • Racial Disparity in Delivering Definitive Therapy for Intermediate/High-risk Localized Prostate Cancer: The Impact of Facility Features and Socioeconomic Characteristics. Eur Urol. 2018 Mar; 73(3):445-451. View in: Pubmed

    • Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer. JAMA Oncol. 2017 Aug 01; 3(8):1085-1093. View in: Pubmed

    • Pathologic correlation of transperineal in-bore 3-Tesla magnetic resonance imaging-guided prostate biopsy samples with radical prostatectomy specimen. Abdom Radiol (NY). 2017 08; 42(8):2154-2159. View in: Pubmed

    • Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry. J Natl Cancer Inst. 2017 08 01; 109(8). View in: Pubmed

    • Caution with Use of the EPIC-50 Urinary Bother Scale: How Voiding Dysfunction Modifies its Performance. J Urol. 2017 12; 198(6):1397-1403. View in: Pubmed

    • The Use of Prostate Specific Antigen Screening in Purchased versus Direct Care Settings: Data from the TRICARE® Military Database. J Urol. 2017 12; 198(6):1295-1300. View in: Pubmed

    • Intermediate Risk Prostate Cancer and Active Surveillance: Maximize Utilization while Minimizing Failure. J Urol. 2017 09; 198(3):493-495. View in: Pubmed

    • The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. Cancer. 2017 Sep 15; 123(18):3532-3539. View in: Pubmed

    • Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population Based Analysis Comparing Radical Prostatectomy versus External Beam Radiation. J Urol. 2017 11; 198(5):1061-1068. View in: Pubmed

    • Androgen receptor-regulated miRNA-193a-3p targets AJUBA to promote prostate cancer cell migration. Prostate. 2017 Jun; 77(9):1000-1011. View in: Pubmed

    • Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PRO-IMPACT study. Cancer. 2017 Aug 01; 123(15):2850-2859. View in: Pubmed

    • Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder. Eur Urol. 2017 10; 72(4):483-487. View in: Pubmed

    • Adverse pathologic characteristics in the small renal mass: implications for active surveillance. Can J Urol. 2017 Apr; 24(2):8759-8764. View in: Pubmed

    • SNP interaction pattern identifier (SIPI): an intensive search for SNP-SNP interaction patterns. Bioinformatics. 2017 03 15; 33(6):822-833. View in: Pubmed

    • Prophylactic Antibiotics and Postoperative Complications of Radical Cystectomy: A Population Based Analysis in the United States. J Urol. 2017 08; 198(2):297-304. View in: Pubmed

    • Assessing robot-assisted laparoscopic prostatectomy. Lancet. 2017 02 25; 389(10071):799. View in: Pubmed

    • 10-Year Outcomes in Localized Prostate Cancer. N Engl J Med. 2017 01 12; 376(2):178. View in: Pubmed

    • Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. J Clin Oncol. 2017 Mar 10; 35(8):852-860. View in: Pubmed

    • The association of hypoalbuminemia with early perioperative outcomes - A comprehensive assessment across 16 major procedures. Am J Surg. 2017 Nov; 214(5):871-883. View in: Pubmed

    • Risk of Small Bowel Obstruction After Robot-Assisted vs Open Radical Prostatectomy. J Endourol. 2016 12; 30(12):1291-1295. View in: Pubmed

    • Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial. Clin Cancer Res. 2017 May 15; 23(10):2451-2459. View in: Pubmed

    • Neoadjuvant Enzalutamide Prior to Prostatectomy. Clin Cancer Res. 2017 May 01; 23(9):2169-2176. View in: Pubmed

    • Prog Urol. 2016 Nov; 26(13):676-677. View in: Pubmed

    • Investigating the possible causal role of coffee consumption with prostate cancer risk and progression using Mendelian randomization analysis. Int J Cancer. 2017 Jan 15; 140(2):322-328. View in: Pubmed

    • 30-Day Adverse Events Following Cystectomy for Bladder Cancer Versus Benign Bladder Conditions. Urol Pract. 2017 Sep; 4(5):388-394. View in: Pubmed

    • A Nationwide Survey of Prostate Specific Antigen Based Screening and Counseling for Prostate Cancer. Urol Pract. 2017 May; 4(3):210-217. View in: Pubmed

    • Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base. J Clin Oncol. 2016 10 10; 34(29):3529-3536. View in: Pubmed

    • Alcohol consumption and prostate cancer incidence and progression: A Mendelian randomisation study. Int J Cancer. 2017 Jan 01; 140(1):75-85. View in: Pubmed

    • NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Netw. 2016 10; 14(10):1213-1224. View in: Pubmed

    • Human vascular progenitor cells derived from renal arteries are endothelial-like and assist in the repair of injured renal capillary networks. Kidney Int. 2017 01; 91(1):129-143. View in: Pubmed

    • Meat, Fish, Poultry, and Egg Intake at Diagnosis and Risk of Prostate Cancer Progression. Cancer Prev Res (Phila). 2016 Dec; 9(12):933-941. View in: Pubmed

    • PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. J Med Genet. 2016 12; 53(12):800-811. View in: Pubmed

    • Relief of Urinary Symptom Burden after Primary Prostate Cancer Treatment. J Urol. 2017 02; 197(2):376-384. View in: Pubmed

    • Resident Involvement in Radical Inguinal Orchiectomy for Testicular Cancer Does Not Adversely Impact Perioperative Outcomes - A Retrospective Study. Urol Int. 2017; 98(4):472-477. View in: Pubmed

    • Polyunsaturated fatty acids and prostate cancer risk: a Mendelian randomisation analysis from the PRACTICAL consortium. Br J Cancer. 2016 08 23; 115(5):624-31. View in: Pubmed

    • Rare Variation in TET2 Is Associated with Clinically Relevant Prostate Carcinoma in African Americans. Cancer Epidemiol Biomarkers Prev. 2016 11; 25(11):1456-1463. View in: Pubmed

    • Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discov. 2016 09; 6(9):1052-67. View in: Pubmed

    • Determinants of cancer screening in Asian-Americans. Cancer Causes Control. 2016 08; 27(8):989-98. View in: Pubmed

    • Assessing the role of insulin-like growth factors and binding proteins in prostate cancer using Mendelian randomization: Genetic variants as instruments for circulating levels. Int J Cancer. 2016 10 01; 139(7):1520-33. View in: Pubmed

    • Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer. J Clin Oncol. 2016 08 10; 34(23):2705-11. View in: Pubmed

    • Surgeon and Hospital Level Variation in the Costs of Robot-Assisted Radical Prostatectomy. J Urol. 2016 Oct; 196(4):1090-5. View in: Pubmed

    • The Effect of Resident Involvement on Surgical Outcomes for Common Urologic Procedures: A Case Study of Uni- and Bilateral Hydrocele Repair. Urology. 2016 Aug; 94:70-6. View in: Pubmed

    • Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array. Br J Cancer. 2016 04 12; 114(8):945-52. View in: Pubmed

    • Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. Nat Commun. 2016 Apr 07; 7:10979. View in: Pubmed

    • Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort. BMC Med. 2016 Apr 04; 14:66. View in: Pubmed

    • Trends of acute kidney injury after radical or partial nephrectomy for renal cell carcinoma. Urol Oncol. 2016 07; 34(7):293.e1-293.e10. View in: Pubmed

    • Blood lipids and prostate cancer: a Mendelian randomization analysis. Cancer Med. 2016 06; 5(6):1125-36. View in: Pubmed

    • Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer. Oncogene. 2016 09 08; 35(36):4807-15. View in: Pubmed

    • Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer. JAMA Oncol. 2016 Jan; 2(1):85-93. View in: Pubmed

    • Genetic variants in cell cycle control pathway confer susceptibility to aggressive prostate carcinoma. Prostate. 2016 Apr; 76(5):479-90. View in: Pubmed

    • Causes of hospital readmissions after urologic cancer surgery. Urol Oncol. 2016 May; 34(5):236.e1-11. View in: Pubmed

    • Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer. Can J Urol. 2015 Dec; 22(6):8048-55. View in: Pubmed

    • Racial/Ethnic Disparities in Perioperative Outcomes of Major Procedures: Results From the National Surgical Quality Improvement Program. Ann Surg. 2015 Dec; 262(6):955-64. View in: Pubmed

    • Complications Following Common Inpatient Urological Procedures: Temporal Trend Analysis from 2000 to 2010. Eur Urol Focus. 2016 Apr; 2(1):3-9. View in: Pubmed

    • Treatment Decision Making in Patients with Bladder Cancer. Bladder Cancer. 2015 Oct 26; 1(2):151-158. View in: Pubmed

    • The Effect of Body Mass Index on Perioperative Outcomes After Major Surgery: Results from the National Surgical Quality Improvement Program (ACS-NSQIP) 2005-2011. World J Surg. 2015 Oct; 39(10):2376-85. View in: Pubmed

    • Calcium intake, polymorphisms of the calcium-sensing receptor, and recurrent/aggressive prostate cancer. Cancer Causes Control. 2015 Dec; 26(12):1751-9. View in: Pubmed

    • Suicide and accidental deaths among patients with non-metastatic prostate cancer. BJU Int. 2016 Aug; 118(2):286-97. View in: Pubmed

    • The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium. Cancer Causes Control. 2015 Nov; 26(11):1603-16. View in: Pubmed

    • Racial Disparities in End-of-Life Care Among Patients With Prostate Cancer: A Population-Based Study. J Natl Compr Canc Netw. 2015 Sep; 13(9):1131-8. View in: Pubmed

    • The Contemporary Incidence and Sequelae of Rhabdomyolysis Following Extirpative Renal Surgery: A Population Based Analysis. J Urol. 2016 Feb; 195(2):399-405. View in: Pubmed

    • Contemporary nationwide patterns of self-reported prostate-specific antigen screening in US veterans. Urol Oncol. 2015 Dec; 33(12):503.e7-15. View in: Pubmed

    • Temporal trends in receipt of adequate lymphadenectomy in bladder cancer 1988 to 2010. Urol Oncol. 2015 Dec; 33(12):504.e9-17. View in: Pubmed

    • Genome-wide association study of prostate cancer-specific survival. Cancer Epidemiol Biomarkers Prev. 2015 Nov; 24(11):1796-800. View in: Pubmed

    • Dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events. BJU Int. 2016 08; 118(2):221-9. View in: Pubmed

    • Medical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged =66 years. Eur J Surg Oncol. 2015 Nov; 41(11):1529-39. View in: Pubmed

    • Prediction of individual genetic risk to prostate cancer using a polygenic score. Prostate. 2015 Sep; 75(13):1467-74. View in: Pubmed

    • A Comparison of 30-Day Perioperative Outcomes in Open Versus Minimally Invasive Nephroureterectomy for Upper Tract Urothelial Carcinoma: Analysis of 896 Patients from the American College of Surgeons-National Surgical Quality Improvement Program Database. J Endourol. 2015 Sep; 29(9):1052-8. View in: Pubmed

    • An evaluation of the 'weekend effect' in patients admitted with metastatic prostate cancer. BJU Int. 2015 Dec; 116(6):911-9. View in: Pubmed

    • Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. Hum Mol Genet. 2015 Oct 01; 24(19):5589-602. View in: Pubmed

    • The Effect of Resident Involvement on Perioperative Outcomes in Transurethral Urologic Surgeries. J Surg Educ. 2015 Sep-Oct; 72(5):1018-25. View in: Pubmed

    • Comparison of 30-day perioperative outcomes in adults undergoing open versus minimally invasive pyeloplasty for ureteropelvic junction obstruction: analysis of 593 patients in a prospective national database. World J Urol. 2015 Dec; 33(12):2107-13. View in: Pubmed

    • Impact of smoking on perioperative outcomes after major surgery. Am J Surg. 2015 Aug; 210(2):221-229.e6. View in: Pubmed

    • New trends in the surgical management of invasive bladder cancer. Hematol Oncol Clin North Am. 2015 Apr; 29(2):253-69, viii. View in: Pubmed

    • Prediagnostic Body-mass Index, Smoking and Prostate Cancer Survival: A Cohort Consortium Study of Over 10,000 White Men with Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2015 Apr; 24(4):759-60. View in: Pubmed

    • The impact of resident involvement in male one-stage anterior urethroplasties. Urology. 2015 Apr; 85(4):937-41. View in: Pubmed

    • A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer. Cancer Discov. 2015 Apr; 5(4):368-79. View in: Pubmed

    • Urolithiasis and urinary tract infection among patients with inflammatory bowel disease: a review of US emergency department visits between 2006 and 2009. Urology. 2015 Apr; 85(4):764-70. View in: Pubmed

    • Burden of hospital admissions and utilization of hospice care in metastatic prostate cancer patients. Urology. 2015 Feb; 85(2):343-9. View in: Pubmed

    • The RAZOR (randomized open vs robotic cystectomy) trial: study design and trial update. BJU Int. 2015 Feb; 115(2):198-205. View in: Pubmed

    • Effect of preoperative angina pectoris on cardiac outcomes in patients with previous myocardial infarction undergoing major noncardiac surgery (data from ACS-NSQIP). Am J Cardiol. 2015 Apr 15; 115(8):1080-4. View in: Pubmed

    • Impact of surgeon volume on the morbidity and costs of radical cystectomy in the USA: a contemporary population-based analysis. BJU Int. 2015 May; 115(5):713-21. View in: Pubmed

    • Readmissions after major urologic cancer surgery. Can J Urol. 2014 Dec; 21(6):7537-46. View in: Pubmed

    • Words of wisdom. Re: Enzalutamide in metastatic prostate cancer before chemotherapy. Eur Urol. 2015 Jan; 67(1):174. View in: Pubmed

    • Can urinary PCA3 supplement PSA in the early detection of prostate cancer? J Clin Oncol. 2014 Dec 20; 32(36):4066-72. View in: Pubmed

    • Contemporary nationwide patterns of self-reported prostate-specific antigen screening. JAMA Intern Med. 2014 Nov; 174(11):1839-41. View in: Pubmed

    • Castration-resistant prostate cancer: AUA guideline amendment. J Urol. 2015 Feb; 193(2):491-9. View in: Pubmed

    • The burden of skeletal-related events in patients with prostate cancer and bone metastasis. Urol Oncol. 2015 Jan; 33(1):17.e9-17.e18. View in: Pubmed

    • Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer. Eur Urol. 2015 Jul; 68(1):32-9. View in: Pubmed

    • Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy. Eur Urol. 2015 Jun; 67(6):1160-1167. View in: Pubmed

    • Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer-specific mortality by nomogram-predicted risks of biochemical recurrence. Eur Urol. 2015 Feb; 67(2):204-9. View in: Pubmed

    • Effect of minimally invasive surgery on the risk for surgical site infections: results from the National Surgical Quality Improvement Program (NSQIP) Database. JAMA Surg. 2014 Oct; 149(10):1039-44. View in: Pubmed

    • Defining a standard set of patient-centered outcomes for men with localized prostate cancer. Eur Urol. 2015 Mar; 67(3):460-7. View in: Pubmed

    • Transperineal in-bore 3-T MR imaging-guided prostate biopsy: a prospective clinical observational study. Radiology. 2015 Jan; 274(1):170-80. View in: Pubmed

    • A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet. 2014 Oct; 46(10):1103-9. View in: Pubmed

    • The impact of resident involvement in minimally-invasive urologic oncology procedures. Can Urol Assoc J. 2014 Sep; 8(9-10):334-40. View in: Pubmed

    • Short-term perioperative outcomes of patients treated with radical cystectomy for bladder cancer included in the National Surgical Quality Improvement Program (NSQIP) database. Can Urol Assoc J. 2014 Sep; 8(9-10):E681-7. View in: Pubmed

    • The impact of robotic surgery on the surgical management of prostate cancer in the USA. BJU Int. 2015 Jun; 115(6):929-36. View in: Pubmed

    • Preventable mortality after common urological surgery: failing to rescue? BJU Int. 2015 Apr; 115(4):666-74. View in: Pubmed

    • Mental health outcomes in elderly men with prostate cancer. Urol Oncol. 2014 Nov; 32(8):1333-40. View in: Pubmed

    • Predictors of 30-day acute kidney injury following radical and partial nephrectomy for renal cell carcinoma. Urol Oncol. 2014 Nov; 32(8):1259-66. View in: Pubmed

    • Generalizability of established prostate cancer risk variants in men of African ancestry. Int J Cancer. 2015 Mar 01; 136(5):1210-7. View in: Pubmed

    • Chronic kidney disease and perioperative outcomes in urological oncological surgery. Int J Urol. 2014 Dec; 21(12):1245-52. View in: Pubmed

    • International Robotic Radical Cystectomy Consortium: A way forward. Indian J Urol. 2014 Jul; 30(3):314-7. View in: Pubmed

    • Efficacy of robot-assisted radical cystectomy (RARC) in advanced bladder cancer: results from the International Radical Cystectomy Consortium (IRCC). BJU Int. 2014 Jul; 114(1):98-103. View in: Pubmed

    • Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol. 2014 Jun 20; 32(18):1889-94. View in: Pubmed

    • Comparative effectiveness of robot-assisted and open radical prostatectomy in the postdissemination era. J Clin Oncol. 2014 May 10; 32(14):1419-26. View in: Pubmed

    • Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base. Int J Radiat Oncol Biol Phys. 2014 Apr 01; 88(5):1048-56. View in: Pubmed

    • Local treatment of high risk prostate cancer: Role of surgery and radiation therapy. Cancer. 2014 Jun 01; 120(11):1608-10. View in: Pubmed

    • Morbidity and mortality after benign prostatic hyperplasia surgery: data from the American College of Surgeons national surgical quality improvement program. J Endourol. 2014 Jul; 28(7):831-40. View in: Pubmed

    • Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC). BJU Int. 2014 May; 113(5b):E67-74. View in: Pubmed

    • Fine-mapping the HOXB region detects common variants tagging a rare coding allele: evidence for synthetic association in prostate cancer. PLoS Genet. 2014 Feb; 10(2):e1004129. View in: Pubmed

    • Propensity-matched comparison of morbidity and costs of open and robot-assisted radical cystectomies: a contemporary population-based analysis in the United States. Eur Urol. 2014 Sep; 66(3):569-76. View in: Pubmed

    • Prostate cancer (PCa) risk variants and risk of fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Eur Urol. 2014 Jun; 65(6):1069-75. View in: Pubmed

    • A guide for clinicians in the evaluation of emerging molecular diagnostics for newly diagnosed prostate cancer. Rev Urol. 2014; 16(4):172-80. View in: Pubmed

    • The health care burden of skeletal related events in patients with renal cell carcinoma and bone metastasis. J Urol. 2014 Jun; 191(6):1678-84. View in: Pubmed

    • Reply to Michael Froehner's letter to the editor re: Kenneth G. Nepple, Andrew J. Stephenson, Dorina Kallogjeri, et al. Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity. Eur Urol 2013;64:372-8. Eur Urol. 2014 Mar; 65(3):e42. View in: Pubmed

    • Analysis of intracorporeal compared with extracorporeal urinary diversion after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. Eur Urol. 2014 Feb; 65(2):340-7. View in: Pubmed

    • Predicting risk of bladder cancer using clinical and demographic information from prostate, lung, colorectal, and ovarian cancer screening trial participants. Cancer Epidemiol Biomarkers Prev. 2013 Dec; 22(12):2241-9. View in: Pubmed

    • Early detection, PSA screening, and management of overdiagnosis. Hematol Oncol Clin North Am. 2013 Dec; 27(6):1091-110, vii. View in: Pubmed

    • Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials. Cancer. 2013 Oct 15; 119(20):3610-8. View in: Pubmed

    • Constitutive ß-catenin activation induces male-specific tumorigenesis in the bladder urothelium. Cancer Res. 2013 Oct 01; 73(19):5914-25. View in: Pubmed

    • Words of wisdom. Re: Intermittent androgen suppression for rising PSA level after radiotherapy. Eur Urol. 2013 Jun; 63(6):1129-30. View in: Pubmed

    • Castration-resistant prostate cancer: AUA Guideline. J Urol. 2013 Aug; 190(2):429-38. View in: Pubmed

    • Response to Letter to the Editor. J Urol. 2013 Apr 10. View in: Pubmed

    • Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet. 2013 Apr; 45(4):385-91, 391e1-2. View in: Pubmed

    • Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Hum Mol Genet. 2013 Jun 15; 22(12):2520-8. View in: Pubmed

    • Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity. Eur Urol. 2013 Sep; 64(3):372-8. View in: Pubmed

    • 11C-acetate PET/CT before radical prostatectomy: nodal staging and treatment failure prediction. J Nucl Med. 2013 May; 54(5):699-706. View in: Pubmed

    • Reply from authors re: Manfred P. Wirth, Johannes Huber. What really matters is rarely measured: outcome of routine care and patient-reported outcomes. Eur Urol 2013;64:58-9: robot-assisted versus open radical cystectomy: beating a dead horse. Eur Urol. 2013 Jul; 64(1):60-1. View in: Pubmed

    • Impact of surgeon and volume on extended lymphadenectomy at the time of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium (IRCC). BJU Int. 2013 Jun; 111(7):1075-80. View in: Pubmed

    • Randomized phase II trial evaluating the optimal sequencing of sipuleucel-T and androgen-deprivation therapy (ADT) in patients (pts) with biochemically recurrent prostate cancer (BRPC). J Clin Oncol. 2013 Feb 20; 31(6_suppl):34. View in: Pubmed

    • Clinical-pathologic stage discrepancy in patients with bladder cancer treated with radical cystectomy: Associations with clinical variables and survival. J Clin Oncol. 2013 Feb 20; 31(6_suppl):248. View in: Pubmed

    • Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african descent. Prostate Cancer. 2013; 2013:560857. View in: Pubmed

    • The 2011-2016 Transdisciplinary Research on Energetics and Cancer (TREC) initiative: rationale and design. Cancer Causes Control. 2013 Apr; 24(4):695-704. View in: Pubmed

    • Editorial comment. J Urol. 2013 Mar; 189(3):853. View in: Pubmed

    • Complications after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. Eur Urol. 2013 Jul; 64(1):52-7. View in: Pubmed

    • To biopsy or not to biopsy: minimizing the risk of prostate needle biopsy. J Urol. 2013 Mar; 189(3):796-7. View in: Pubmed

    • Randomized controlled trial of oxybutynin extended release versus placebo for urinary symptoms during intravesical Bacillus Calmette-Guérin treatment. J Urol. 2013 Apr; 189(4):1268-74. View in: Pubmed

    • Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care. Eur Urol. 2013 Feb; 63(2):214-30. View in: Pubmed

    • Urologic Clinics of North America. Castrate-resistant prostate cancer. Preface. Urol Clin North Am. 2012 Nov; 39(4):xv. View in: Pubmed

    • Who should be included in a clinical trial of screening for bladder cancer?: a decision analysis of data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Cancer. 2013 Jan 01; 119(1):143-9. View in: Pubmed

    • Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample. Eur Urol. 2012 Jun; 61(6):1239-44. View in: Pubmed

    • Androgen deprivation therapy for localized and nonmetastatic prostate cancer: too much of a good thing? Eur Urol. 2012 Jun; 61(6):1129-30; discussion 1131. View in: Pubmed

    • Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era. J Urol. 2012 Apr; 187(4):1259-65. View in: Pubmed

    • Prostate cancer-specific mortality and competing causes of mortality among elderly men after local therapy for prostate cancer. J Clin Oncol. 2012 Feb 10; 30(5_suppl):103. View in: Pubmed

    • Impact of different definitions of high-risk prostate cancer on survival after radical prostatectomy. J Clin Oncol. 2012 Feb 10; 30(5_suppl):113. View in: Pubmed

    • Impact of marital status on prostate cancer-specific mortality and overall mortality after radical prostatectomy. J Clin Oncol. 2012 Feb 10; 30(5_suppl):73. View in: Pubmed

    • Foamy gland adenocarcinoma of the prostate: incidence, Gleason grade, and early clinical outcome. Hum Pathol. 2012 Jul; 43(7):974-9. View in: Pubmed

    • Ureteral injury in laparoscopic gynecologic surgery. Rev Obstet Gynecol. 2012; 5(2):106-11. View in: Pubmed

    • Treat now or later: the dilemma of postoperative radiotherapy. Eur Urol. 2012 Mar; 61(3):452-4. View in: Pubmed

    • Highlights of the 2010 SUO Annual Meeting. Urol Oncol. 2011 Nov-Dec; 29(6):825. View in: Pubmed

    • Indications and practice with androgen deprivation therapy. Urology. 2011 Nov; 78(5 Suppl):S478-81. View in: Pubmed

    • Targeting the androgen receptor--theory and practice. Urology. 2011 Nov; 78(5 Suppl):S482-4. View in: Pubmed

    • Prediction of erectile function following treatment for prostate cancer. JAMA. 2011 Sep 21; 306(11):1205-14. View in: Pubmed

    • Laparoscopic retroperitoneal lymph node dissection for low-stage cancer: a Washington University update. J Endourol. 2011 Nov; 25(11):1753-7. View in: Pubmed

    • Early oncologic outcomes of robotic vs. open radical cystectomy for urothelial cancer. Urol Oncol. 2013 Aug; 31(6):894-8. View in: Pubmed

    • Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet. 2011 Jun; 43(6):570-3. View in: Pubmed

    • A retrospective validation of a circulating microvesicle-based assay for the detection of prostate cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):e15172. View in: Pubmed

    • Design of an open-label randomized phase II trial examining the effect of sequencing of sipuleucel-T and androgen deprivation therapy (ADT) on immune markers in prostate cancer patients with a rising prostate specific antigen (PSA) after primary therapy. J Clin Oncol. 2011 May 20; 29(15_suppl):TPS189. View in: Pubmed

    • Words of wisdom. Re: active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. Eur Urol. 2011 May; 59(5):883-4. View in: Pubmed

    • Positive margin during partial nephrectomy: does cancer remain in the renal remnant? Urology. 2011 Jun; 77(6):1400-3. View in: Pubmed

    • Prostate cancer predisposition loci and risk of metastatic disease and prostate cancer recurrence. Clin Cancer Res. 2011 Mar 01; 17(5):1075-81. View in: Pubmed

    • Lymphadenectomy at the time of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. BJU Int. 2011 Feb; 107(4):642-6. View in: Pubmed

    • Ability of linear length of positive margin in radical prostatectomy specimens to predict biochemical recurrence. Urology. 2011 Jun; 77(6):1409-14. View in: Pubmed

    • Validation of genome-wide prostate cancer associations in men of African descent. Cancer Epidemiol Biomarkers Prev. 2011 Jan; 20(1):23-32. View in: Pubmed

    • Editorial for "Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50". Cancer. 2011 Mar 15; 117(6):1110-2. View in: Pubmed

    • Does previous robot-assisted radical prostatectomy experience affect outcomes at robot-assisted radical cystectomy? Results from the International Robotic Cystectomy Consortium. Urology. 2010 Nov; 76(5):1111-6. View in: Pubmed

    • The Gleason score of tumor at the margin in radical prostatectomy is predictive of biochemical recurrence. Am J Surg Pathol. 2010 Jul; 34(7):994-1001. View in: Pubmed

    • Counterpoint: Prostate carcinoma treatment for the young patient--The case for radical prostatectomy. Brachytherapy. 2010 Jul-Sep; 9(3):195-8; discussion 199-201. View in: Pubmed

    • Reply from authors re: Urs E. Studer, Laurence Collette. Robot-assisted cystectomy: does it meet expectations? Eur Urol 2010;58:203-4. Eur Urol. 2010 Aug; 58(2):204-6. View in: Pubmed

    • Surgical margin status after robot assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. J Urol. 2010 Jul; 184(1):87-91. View in: Pubmed

    • BCAN Think Tank session 3: Prevention of bladder cancer. Urol Oncol. 2010 May-Jun; 28(3):338-42. View in: Pubmed

    • High-risk localized prostate cancer: role of radical prostatectomy. Curr Opin Urol. 2010 May; 20(3):204-10. View in: Pubmed

    • Association of CASP8 D302H polymorphism with reduced risk of aggressive prostate carcinoma. Prostate. 2010 May 01; 70(6):646-53. View in: Pubmed

    • The learning curve of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. Eur Urol. 2010 Aug; 58(2):197-202. View in: Pubmed

    • Percent microscopic tumor necrosis and survival after curative surgery for renal cell carcinoma. J Urol. 2010 Mar; 183(3):909-14. View in: Pubmed

    • Risk of urinary incontinence following prostatectomy: the role of physical activity and obesity. J Urol. 2010 Feb; 183(2):629-33. View in: Pubmed

    • Editorial comment. J Urol. 2010 Feb; 183(2):533; discussion 533. View in: Pubmed

    • Effect of reclassification on the incidence of benign and malignant renal tumors. J Urol. 2010 Feb; 183(2):455-8. View in: Pubmed

    • Words of wisdom. Re: Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. Eur Urol. 2009 Dec; 56(6):1089-90. View in: Pubmed

    • The role of lymphovascular space invasion in renal cell carcinoma as a prognostic marker of survival after curative resection. Urol Oncol. 2011 Nov-Dec; 29(6):738-44. View in: Pubmed

    • Editorial comment. J Urol. 2009 Nov; 182(5):2194; discussion 2194. View in: Pubmed

    • Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol. 2009 Sep 10; 27(26):4314-20. View in: Pubmed

    • Intravesical bacille Calmette-Guérin therapy for non-muscle-invasive bladder cancer: effects of concurrent statin therapy. J Am Coll Surg. 2009 Aug; 209(2):248-53. View in: Pubmed

    • Prostate cancer risk associated loci in African Americans. Cancer Epidemiol Biomarkers Prev. 2009 Jul; 18(7):2145-9. View in: Pubmed

    • Highlights of the 2008 SUO/SBUR annual meeting: current controversies in urologic oncology. Urol Oncol. 2009 May-Jun; 27(3):293-4. View in: Pubmed

    • Magnetic resonance diffusion characteristics of histologically defined prostate cancer in humans. Magn Reson Med. 2009 Apr; 61(4):842-50. View in: Pubmed

    • Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk. Carcinogenesis. 2009 May; 30(5):769-76. View in: Pubmed

    • The role of systemic cytotoxic therapy for prostate cancer. BJU Int. 2009 Jan; 103(1):8-17. View in: Pubmed

    • Variation in KLK genes, prostate-specific antigen and risk of prostate cancer. Nat Genet. 2008 Sep; 40(9):1032-4; author reply 1035-6. View in: Pubmed

    • Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer. BJU Int. 2008 Aug 05; 102(5):546-50. View in: Pubmed

    • Association between polymorphisms in cell cycle genes and advanced prostate carcinoma. Prostate. 2008 Aug 01; 68(11):1179-86. View in: Pubmed

    • Percentage of high-grade carcinoma as a prognostic indicator in patients with renal cell carcinoma. Cancer. 2008 Aug 01; 113(3):477-83. View in: Pubmed

    • Laparoscopic retroperitoneal lymph node dissection for low-stage testicular cancer. J Endourol. 2008 Jul; 22(7):1485-9. View in: Pubmed

    • Impact of central pathology review (CPR) of radical prostatectomy (RP) specimens for patient selection in the surgical adjuvant trial in prostate cancer (PCa) TAX-3501. J Clin Oncol. 2008 May 20; 26(15_suppl):5128. View in: Pubmed

    • Impact of comorbidity on overall survival in patients surgically treated for renal cell carcinoma. Urology. 2008 Aug; 72(2):359-63. View in: Pubmed

    • Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008 Mar 20; 358(12):1250-61. View in: Pubmed

    • The distribution of histological subtypes of renal tumors by decade of life using the 2004 WHO classification. J Urol. 2008 Feb; 179(2):439-43; discussion 443-4. View in: Pubmed

    • SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer. Hum Mol Genet. 2008 Apr 01; 17(7):1031-42. View in: Pubmed

    • Words of wisdom. Re: EPCA-2: a highly specific serum marker for prostate cancer. Eur Urol. 2008 Jan; 53(1):210. View in: Pubmed

    • The Second Joint Meeting of American Urological Association (AUA)/Japanese Urological Association (JUA) International Program on the 102nd Annual Meeting of American Urological Association at Anaheim 2007. Int J Urol. 2007 Dec; 14(12):1116-23. View in: Pubmed

    • Prognostic impact of comorbidity in patients with bladder cancer. Eur Urol. 2008 Mar; 53(3):581-9. View in: Pubmed

    • Prostate cancer: screening, diagnosis and management in 2007. Mo Med. 2007 Sep-Oct; 104(5):408-13; quiz 413-4. View in: Pubmed

    • The use and abuse of data: nomograms and talking to patients about clinical medicine. Urol Oncol. 2007 Jul-Aug; 25(4):333-7. View in: Pubmed

    • Optimizing prostate biopsy techniques. J Urol. 2007 Jun; 177(6):1976-7. View in: Pubmed

    • Prostate-specific antigen density predicts adverse pathology and increased risk of biochemical failure. Urology. 2007 Jun; 69(6):1121-7. View in: Pubmed

    • Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol. 2007 May; 177(5):1777-81. View in: Pubmed

    • Adjuvant and salvage treatment options for patients with high-risk prostate cancer treated with radical prostatectomy. Prostate Cancer Prostatic Dis. 2007; 10(2):119-26. View in: Pubmed

    • Trends in nephron-sparing surgery for renal neoplasia. Urology. 2006 Oct; 68(4):732-6. View in: Pubmed

    • Minimally invasive approaches to localized prostate carcinoma. Hematol Oncol Clin North Am. 2006 Aug; 20(4):879-95. View in: Pubmed

    • Single nucleotide polymorphisms: early diagnosis and risk assessment in genitourinary malignancy. Urol Oncol. 2006 May-Jun; 24(3):224-30. View in: Pubmed

    • Association of hereditary prostate cancer gene polymorphic variants with sporadic aggressive prostate carcinoma. Prostate. 2006 Jan 01; 66(1):49-56. View in: Pubmed

    • Laparoscopic renal surgery and the risk of rhabdomyolysis: diagnosis and treatment. Urology. 2005 Nov; 66(5 Suppl):29-35. View in: Pubmed

    • A pilot multicenter phase II study of adjuvant docetaxel (D) for high risk prostate cancer (PC) patients (pts) after radical prostatectomy (RP): Preliminary data. J Clin Oncol. 2005 Jun; 23(16_suppl):4565. View in: Pubmed

    • An interdisciplinary approach to treating prostate cancer. Urology. 2005 Jun; 65(6 Suppl):13-8. View in: Pubmed

    • Parenchymal imaging adds diagnostic utility in evaluating haematuria. BJU Int. 2005 Jan; 95(1):64-7. View in: Pubmed

    • Adjuvant weekly docetaxel (D) for high-risk prostate cancer patients (pts) after radical prostatectomy (RP): Preliminary data of a multicenter pilot trial. J Clin Oncol. 2004 Jul 15; 22(14_suppl):4649. View in: Pubmed

    • Expression mapping at 12p12-13 in advanced prostate carcinoma. Int J Cancer. 2004 May 01; 109(5):668-72. View in: Pubmed

    • Transitional cell carcinoma of the renal pelvis associated with hypercalcemia in a patient with autosomal dominant polycystic kidney disease. Urology. 2004 Apr; 63(4):778-80. View in: Pubmed

    • Renal sinus haemangioma with inferior vena cava involvement. BJU Int. 2003 Dec; 92 Suppl 3:e53. View in: Pubmed

    • Surgical treatment of renal neoplasia: evolving toward a laparoscopic standard of care. Urology. 2003 Nov; 62(5):821-6. View in: Pubmed

    • Modified renal morcellation for renal cell carcinoma: laboratory experience and early clinical application. Urology. 2003 Oct; 62(4):632-4; discussion 635. View in: Pubmed

    • Xq27-28 deletions in prostate carcinoma. Genes Chromosomes Cancer. 2003 Aug; 37(4):381-8. View in: Pubmed

    • CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. Cancer Res. 2003 May 01; 63(9):2033-6. View in: Pubmed

    • Hemostatic laparoscopic partial nephrectomy assisted by a water-cooled, high-density, monopolar device without renal vascular control. Urology. 2003 May; 61(5):906-9. View in: Pubmed

    • 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med. 2003 Apr; 44(4):549-55. View in: Pubmed

    • Laparoscopic partial nephrectomy with a novel electrosurgical snare in a porcine model. J Endourol. 2002 Nov; 16(9):673-9. View in: Pubmed

    • Patterns of multiple recurrences of superficial (Ta/T1) transitional cell carcinoma of bladder and effects of clinicopathologic and biochemical factors. Cancer. 2002 Sep 15; 95(6):1239-46. View in: Pubmed

    • Mutational analysis of ETV6 in prostate carcinoma. Prostate. 2002 Sep 01; 52(4):305-10. View in: Pubmed

    • Comparison of hand assisted and standard laparoscopic radical nephroureterectomy for the management of localized transitional cell carcinoma. J Urol. 2002 Jun; 167(6):2387-91. View in: Pubmed

    • Management of the postpubertal patient with cryptorchidism: an updated analysis. J Urol. 2002 Mar; 167(3):1329-33. View in: Pubmed

    • Rapid resolution of carbon dioxide pneumothorax (capno-thorax) resulting from diaphragmatic injury during laparoscopic nephrectomy. J Urol. 2002 Mar; 167(3):1387-8. View in: Pubmed

    • Dual-organ ablative surgery using a hand-assisted laparoscopic technique. A report of four cases. Surg Endosc. 2002 Jan; 16(1):215-6. View in: Pubmed

    • Methylation and mutational analysis of p27(kip1) in prostate carcinoma. Prostate. 2001 Sep 15; 48(4):248-53. View in: Pubmed

    • Latent prostate carcinoma in a screened population. Eur Urol. 2001 Apr; 39 Suppl 4:35-6. View in: Pubmed

    • Adult clear cell sarcoma of the kidney with atrial tumor thrombus. J Urol. 2001 Mar; 165(3):896-7. View in: Pubmed

    • Loss of heterozygosity at 12P12-13 in primary and metastatic prostate adenocarcinoma. J Urol. 2000 Jul; 164(1):192-6. View in: Pubmed

    • G(1)/S cell cycle proteins as markers of aggressive prostate carcinoma. Urology. 2000 Mar; 55(3):316-22. View in: Pubmed

    • Deletion mapping at 12p12-13 in metastatic prostate cancer. Genes Chromosomes Cancer. 1999 Jul; 25(3):270-6. View in: Pubmed

    • Familial calcium stone disease: TaqI polymorphism and the vitamin D receptor. J Endourol. 1999 May; 13(4):313-6. View in: Pubmed

    • Identification of 12p as a region of frequent deletion in advanced prostate cancer. Cancer Res. 1998 Dec 15; 58(24):5652-5. View in: Pubmed

    • Vitamin D receptor polymorphisms and lethal prostate cancer. J Urol. 1998 Oct; 160(4):1405-9. View in: Pubmed

    • Penile necrosis after coronary artery bypass grafting. Br J Urol. 1998 Mar; 81(3):508-9. View in: Pubmed

    • Prognostic features of teratomas with malignant transformation: a clinicopathological study of 21 cases. J Urol. 1998 Mar; 159(3):859-63. View in: Pubmed

    • Late venous thromboembolic disease after radical prostatectomy: effect of risk factors, warfarin and early discharge. J Urol. 1997 Dec; 158(6):2211-5. View in: Pubmed

    • Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues. Hum Pathol. 1997 Apr; 28(4):459-64. View in: Pubmed

    • Primary lymphoma of the bladder: a unique cystoscopic appearance. Urology. 1997 Feb; 49(2):276-8. View in: Pubmed

    • Constitutive expression of high levels of prostate-specific antigen in the absence of prostate carcinoma. Urology. 1996 Nov; 48(5):741-6. View in: Pubmed

    • Squamous cell carcinoma of the renal pelvis with inferior vena caval extension. J Urol. 1996 Oct; 156(4):1436. View in: Pubmed

    • Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science. 1995 Sep 08; 269(5229):1444-6. View in: Pubmed

    • Tumour suppression by the human von Hippel-Lindau gene product. Nat Med. 1995 Aug; 1(8):822-6. View in: Pubmed

    • Pathogenesis and prophylaxis of postoperative thromboembolic disease in urological pelvic surgery. J Urol. 1995 Jun; 153(6):1763-74. View in: Pubmed

    • Intraperitoneal bladder rupture after normal vaginal delivery. J Urol. 1995 Mar; 153(3 Pt 1):725-7. View in: Pubmed

    Locations

    Location Avtar

    Dana-Farber Cancer Institute

    450 Brookline Avenue Boston, MA 02215
    Get Directions

    Dana-Farber Cancer Institute

    Location Avtar

    Dana-Farber Cancer Institute

    450 Brookline Avenue Boston, MA 02215
    Get Direction
    42.3374, -71.1082

    Ratings and Comments

    Adam S. Kibel, MD

    About Our Ratings

    Physician Star Rating Comment Block

    Discovery and Insights